ICOS Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICOS Corporation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	2/8/2006 7:39:16 AM
	of 1139

ICOS "neutral," target price reduced Wednesday, February 08, 2006 2:36:14 AM ET Robert W. Baird NEW YORK, February 8 (newratings.com) - Analysts at Robert W Baird reiterate their "neutral" rating on ICOS Corporation (ICOS.NAS), while revising their estimates for the company. The target price has been reduced from $30 to $27. In a research note published this morning, the analysts mention that company has posted its 4Q05 EPS short of the estimates, with the earnings shortfall on account of higher-than-anticipated internal spending. ICOS has guided to Cialis WW revenues at $860 million-$900 million for 2006, short of the estimates and the consensus. The EPS estimate for 2006 has been raised from $0.26 to $0.29, while the EPS estimates for 2007 and 2008 have been reduced from $1.12 to $1.00 and from $1.58 to $1.32, respectively.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next